Clinical trials: Schizo-Affective Type of Psychosis
Schizophrenia, Schizotypal Disorder
Feasibility of a Novel Process-based Treatment for Patients With Psychosis
The purpose of this single-arm feasibility study is to develop and pilot test a novel process-based and modular group therapy approach for patients with acute psychotic symptoms in an inpatient setting.
- Conditions
- Schizophrenia, Schizotypal Disorder, Delusional Disorder, Brief Psychotic Disorder
- Trial name
- PROBAS (NCT04874974)
- Testing
- Metacognitive and Defusion Training
- Where
- Germany
- Volunteers
- 37 people
- Sponsor
- Max-Planck-Institute of Psychiatry
Schizophrenia, Schizoaffective Disorder
Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic Syndrome
The purpose of this study was to determine whether patients with schizophrenia, schizoaffective disorder, or bipolar I disorder who also have metabolic syndrome have a larger decrease in fasting non-high density lipoprotein…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar I Disorder, Metabolic Syndrome
- Trial name
- NCT00857818
- Testing
- Aripiprazole, Oanzapine, risperidone, or quetiapine
- Where
- 14 sites in Canada
- Volunteers
- 64 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Psychotic Disorders, Schizoaffective Disorder
Functional Rehabilitation of Older Patients With Schizophrenia
The primary purpose of this project is to evaluate the efficacy of a group therapy intervention, cognitive behavioral social skills training (CBSST), that teaches social functioning skills and cognitive-behavioral compensatory…
- Conditions
- Psychotic Disorders, Schizoaffective Disorder, Schizophrenia
- Trial name
- NCT00237796
- Testing
- Cognitive Behavioral Social Skills Training (CBSST), Goal Focused Supportive Contact (GFSC)
- Where
- United States
- Volunteers
- 116 people
- Sponsor
- US Department of Veterans Affairs
Schizophrenia, Schizoaffective Disorder
Early Prediction of Clinical Response in Patients With Schizophrenia Treated by Paliperidone ER
Paliperidone ER is a new psychotropic medication for schizophrenia treatment. The studies of 6-week acute treatment and 52-week maintenance treatment showed positive results in patients with schizophrenia and its clinical…
- Trial name
- NCT02075528
- Testing
- Paliperidone ER
- Where
- Taiwan
- Volunteers
- 41 people
- Sponsor
- Taipei City Hospital
Schizo Affective Disorder, Schizophrenia
A Study to Determine Pharmacokinetic Characteristics of LY03010 Versus INVEGA SUSTENNA® in Schizophrenia Patients
This study will look at the Characteristics of LY03010 Versus INVEGA SUSTENNA® in the blood of Schizophrenia Patients
- Conditions
- Schizo Affective Disorder, Schizophrenia, Schizoaffective Disorder
- Trial name
- NCT03751488
- Testing
- LY03010, Invega Sustenna 156 MG in 1 ML Prefilled Syringe
- Where
- 2 sites in United States
- Volunteers
- 48 people
- Sponsor
- Luye Pharma Group Ltd.
Schizophrenia, Bipolar Disorder
Evaluation of A Statewide Program to Prevent Early Mortality and to Promote Fitness in Persons With SMI
The goal of this project, which has not changed, is to evaluate the statewide implementation of a two-component intervention (health promotion plus academic detailing) with respect to consumer outcomes and changes in provider…
- Conditions
- Schizophrenia, Bipolar Disorder, Schizoaffective Disorder
- Trial name
- NCT02334280
- Testing
- In SHAPE
- Where
- 4 sites in United States
- Volunteers
- 120 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia, Psychotic Disorders
A Study Comparing the Efficacy of Long-acting Injectable Risperidone and Olanzapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to document both short-term, as well as long-term efficacy and safety of a long-acting injectable formulation of risperidone, in comparison with olanzapine for the treatment of patients with…
- Trial name
- NCT00236457
- Testing
- risperidone
- Volunteers
- 629 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Insight Impaired
The Effects of Bimodal tDCS on Illness Severity, Insight, Functional Outcomes, Neurocognition and HRV in Schizophrenia
The study aimed to investigate the effects of bimodal anodal transcranial direct current stimulation (tDCS) over bilateral dorsolateral prefrontal cortex (DLPFC) on psychopathological symptoms, insight, psychosocial functioning…
- Conditions
- Schizophrenia, Insight Impaired, Psychotic Symptoms, Schizoaffective Disorder
- Trial name
- NCT03701100
- Testing
- tDCS
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Tri-Service General Hospital (TSGH)
Schizophrenia Disorders, Schizoaffective Disorder
Randomized Clinical Trial of iTEST: A Blended Intervention Targeting Introspective Accuracy
The purpose of this study is to evaluate the effectiveness of a psychosocial intervention called iTEST for people with psychotic disorders that targets introspective accuracy, or the ability to accurately gauge ones abilities.
- Conditions
- Schizophrenia Disorders, Schizoaffective Disorder, Psychotic Disorder
- Trial name
- iTEST R33 (NCT07098169)
- Testing
- iTEST, Active Control
- Where
- 3 sites in United States
- Volunteers
- 201 people
- Sponsor
- University of California, San Diego
Schizophrenia, Schizoaffective Disorder
Comparison of Continuing Olanzapine to Switching to Quetiapine in Overweight or Obese Patients With Schizophrenia and Schizoaffective Disorder
The purposes of this study are to determine: The effectiveness of olanzapine as compared to quetiapine in treating and preventing the recurrence of a variety of symptoms of schizophrenia and schizoaffective disorder in patients…
- Trial name
- NCT00090012
- Testing
- Olanzapine, Quetiapine
- Where
- 25 sites in United States
- Volunteers
- 340 people
- Sponsor
- Eli Lilly and Company
Schizophrenia
Cue-based Intervention in Prospective Memory and Medication Adherence.
Medication adherence is a major challenge while treating patients with major mental illnesses like schizophrenia and schizoaffective disorder.
- Trial name
- NCT06474195
- Testing
- Cue based intervention, Treatment as Usual
- Where
- India
- Volunteers
- 104 people
- Sponsor
- University of Pittsburgh
Schizophrenia, Negative Type; Schizophrenic
Using Transcranial Magnetic Stimulation (TMS) to Understand 'Negative' Symptoms of Schizophrenia
The main purpose of this study is to learn how transcranial magnetic stimulation (TMS) helps improve negative symptoms of schizophrenia.
- Conditions
- Schizophrenia, Negative Type; Schizophrenic, Schizo Affective Disorder
- Trial name
- NCT03648268
- Testing
- repetitive Transcranial Magnetic Stimulation (rTMS)
- Where
- United States
- Volunteers
- 47 people
- Sponsor
- Beth Israel Deaconess Medical Center
Psychotic Disorders, Schizophrenia
Development and Pilot Evaluation of Modified Cognitive Behavioural Therapy for Adolescents With Early Onset Psychosis
In the last decade cognitive behavioural therapy (CBT) approaches for patients with schizophrenia have been developed, which where especially designed to reduce severity of positive symptoms, readmission rates, treatment…
- Conditions
- Psychotic Disorders, Schizophrenia, Schizoaffective Disorder, Delusional Disorder
- Trial name
- mCBT (NCT00465920)
- Testing
- modified cognitive behavioural therapy (mCBT)
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- University of Cologne
Schizophrenia, Psychotic Disorder NOS
The Effect of N-Acetyl Cysteine on Cortical Erosion in Early Stage Schizophrenia
The primary objective of this study is to determine if NAC, added to existing antipsychotic treatment, is superior to placebo for cortical erosion in patients with early stage psychosis.
- Conditions
- Schizophrenia, Psychotic Disorder NOS, Schizoaffective Disorder, Schizophreniform
- Trial name
- Breier-Stanley (NCT01339858)
- Testing
- N-Acetyl Cysteine, sugar pill
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Indiana University
Schizophrenia, Schizoaffective Disorder
Impact of Medication Education on Adherence and Side Effects
Severe mental disorders such as schizophrenia, bipolar disorder, and psychotic depression often require long-term or lifelong medication treatment.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder With Psychotic Features, Major Depressive Disorder With Psychotic Features
- Trial name
- MED-ADHERE (NCT07374588)
- Testing
- Medication Education Program, Routine Psychiatric Inpatient Care
- Where
- Turkey (Türkiye)
- Volunteers
- 64 people
- Sponsor
- Cumhuriyet University
Schizophrenia, Schizophreniform Disorders
Treatment of Schizophrenia With an Omega-3 Fatty Acid (EPA) and Antioxidants
The purpose of this trial is to study the effect of adding the omega-3 fatty acid EPA and/or Vitamins E + C to antipsychotic drugs in younger patients with schizophrenia and related psychoses.
- Conditions
- Schizophrenia, Schizophreniform Disorders, Schizoaffective Disorder, Psychotic Disorders
- Trial name
- NCT00419146
- Testing
- Ethyl-eicosapentaenoic acid (EPA), Vitamins E + C
- Where
- Norway
- Volunteers
- 99 people, healthy volunteers welcome
- Sponsor
- University Hospital, Aker
Schizophrenia, Schizo Affective Disorder
Financial Incentives to Improve Medication Adherence
Medication adherence is a challenge in all of medicine and is associated with multiple negative outcomes. Strategies to better measure and enhance adherence to medication are urgent and necessary to minimize unwanted health…
- Conditions
- Schizophrenia, Schizo Affective Disorder, Bipolar Disorder, Depression
- Trial name
- NCT04191876
- Testing
- Wellth - Financial Incentives
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Northwell Health
Schizophrenia, Bipolar Disorder
Psychosocial Intervention to Reduce Self-stigma and Improve Quality of Life Among People With Mental Illness in Chile
The principal objective of this pilot trial is to evaluate the effectiveness of a psychosocial intervention to reduce self-stigma and improve treatment adherence and quality of life among people with a severe mental illness who…
- Conditions
- Schizophrenia, Bipolar Disorder, Schizoaffective Disorder
- Trial name
- NCT03197168
- Testing
- Intervention to reduce self-stigma among people with mental illness, Control
- Where
- Chile
- Volunteers
- 76 people
- Sponsor
- University of Chile
Schizophrenia, Schizoaffective Disorder
Medical Chart Review of Patients on Long-term Treatment With Long-acting Injectable Risperidone
The purpose of the study is to evaluate the characteristics, clinical responses, and safety issues of patients receiving long-term treatment of Risperidone long-acting injectable.
- Trial name
- NCT00644852
- Testing
- Retrospective chart review study
- Volunteers
- 342 people
- Sponsor
- Johnson & Johnson Taiwan Ltd
Schizophrenia, Schizoaffective Disorder
Pharmacokinetic and Safety Study of LY03004 in Stable Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to characterize the pharmacokinetics (PK) of LY03004 following an escalating single intramuscular injection at 12.5, 25, 37.5, or 50 mg; and to evaluate the safety and tolerability and preliminary…
- Trial name
- LY03004SAD (NCT02055287)
- Testing
- LY03004
- Where
- 2 sites in United States
- Volunteers
- 36 people
- Sponsor
- Luye Pharma Group Ltd.